Liquidia Corporation
HealthcareNASDAQ:LQDA · NASDAQ Capital Market
-$0.40 today
Vol 1.69M · Avg 1.42M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-154.0%
avg -91.8%
ROIC
-20.5%
avg -333.9%
ROA
-21.0%
avg -83.3%
Analysis
ROIC is currently the strongest return metric at -20.5% versus its period average of -333.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Roger A. Jeffs | Chief Executive Officer & Director | $2.12M | — | 64 | $1.04M | 1.17% |
Michael Kaseta | Chief Operating Officer & Chief Financial Officer | $1.41M | — | 50 | $353,356.00 | 0.40% |
Russell Schundler | General Counsel & Corporate Secretary | $1.17M | — | 50 | $610,532.00 | 0.69% |
Rajeev Saggar | Chief Medical Officer | $1.17M | — | 51 | $173,270.00 | 0.19% |
Scott Moomaw | Chief Commercial Officer | $980,961.00 | — | 55 | $184,558.00 | 0.21% |
Harold Alterson | Senior Vice President of Quality | — | — | — | — | — |
Dana Boyle | Chief Accounting Officer | — | — | 41 | $175,342.00 | 0.20% |
Michael Hunter | Senior Vice President of Manufacturing Operations | — | — | — | $353,356.00 | 0.40% |
Matt Snow | Senior Vice President of Sales | — | — | — | — | — |
Jason Adair | Chief Business Officer | — | — | 54 | $214,738.00 | 0.24% |
Frank Bartolini | Senior Vice President of Market Access | — | — | — | — | — |
Beth-Anne Lang | Senior Vice President of Global Regulatory Affairs | — | — | — | — | — |
Michael Post | Senior Vice President of Marketing | — | — | — | $353,356.00 | 0.40% |
Sarah Krepp SPHR | Chief Human Resources Officer | — | — | 44 | $147,019.00 | 0.17% |
Gareth Gwyn | Senior Vice President of Medical Affairs | — | — | — | — | — |
Christian Perez Font | Senior Vice President, Chief Compliance Officer & Associate General Counsel | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$317,894.00
Sells
97
$135.01M
Net Sentiment
$134.69M
Net selling
Most Active
Bloch Stephen M
29 transactions
1–10 of 98
Analysis
Insiders reported 1 buys worth $317,894.00 and 97 sells worth $135.01M over the last 12 months. That adds up to net selling of $134.69M. Bloch Stephen M was the most active insider with 29 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -53.3% | +116.3% (10yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -53.3% over three years. Forward estimates point to Revenue at +116.3% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.79B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Who manages LQDA?
Liquidia Corporation (LQDA) lists 16 active executives. The top listed executive is Harold Alterson, Senior Vice President of Quality.
Are LQDA insiders buying or selling?
Recent insider activity shows net selling of $134.69M.
Explore More
Continue the stock analysis
Jump to another research area for this company.